Antiviral Avigan Moves into COVID-19-based Phase II Clinical Trials in Boston Area

Antiviral Avigan Moves into COVID-19-based Phase II Clinical Trials in Boston Area

Fujifilm Holdings Corp initiated a Phase II clinical trial of its anti-flu drug Avigan for COVID-19 patients in the United States for the first time in the Boston, MA, area involving Brigham and Women’s Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School. In Japan, the Japanese company launches a Phase III Avigan trial for COVID-19 patients in Japan. The drug has produced mixed results. Boston, the world’s leading life sciences industry cluster, is an appropriate place to evaluate this important investigational treatment for COVID-19 patients.

What is Avigan?

TrialSite News first introduced Avigan and received many direct emails of interest from all over the world. Known as Avigan, it is an antiviral drug under development by Toyama Chemical of Japan with activity against many RNA viruses. The drug was also being assessed in China for experimental treatment of SARS-CoV-2 and was found to be effective in treating the infection in two clinical trials in Wuhan and Shenzhen. Avigan has evidenced activity against influenza viruses, West Nile virus, yellow fever virus, foot and mouth disease, and others.

The Study

The Japanese sponsor...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee